Thryv Therapeutics, Inc.
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.lqttrx.com
Clinical Trials
3
Active:1
Completed:2
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Thryv Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT06507839
- Locations
- 🇨🇦
Altasciences, Montreal, Quebec, Canada
Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 1, 2 or 3 Long QT Syndrome (Part 2).
Phase 1
Active, not recruiting
- Conditions
- Long QT Syndrome
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Thryv Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05906732
- Locations
- 🇺🇸
Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States
Phase 1 Study of LQT-1213 in Healthy Adults
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Thryv Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05759962
- Locations
- 🇺🇸
Altasciences Clinical Los Angeles, Inc., Cypress, California, United States
News
No news found